Scientists at Sanford Burnham Prebys Medical Discovery Institute say that a new molecular machinery-targeting drug dubbed SBI-756 demonstrated preclinical evidence of success in a mouse model for melanoma.
After studying the visual responses of fruit flies with different types of Parkinson's disease, biologists at the University of York believe they may be on to a new biomarker that could be used to detect the early-onset form of the disease.
Investigators at the University of Birmingham in the U.K. have published the results of a small but intriguing study that has highlighted the potential of Novo Nordisk's blockbuster diabetes drug Victoza (liraglutide) for NASH, an increasingly common liver disease.
Investigators at The Ohio State University Comprehensive Cancer Center say they've nailed down fresh preclinical evidence that an experimental HDAC inhibitor can guard against muscle wasting in cancer cases.
A new mouse study conducted by scientists at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai has pointed to another way that checkpoint inhibitors can play an important part of a combination therapy in attacking cancer.
Nanocarriers are microscopic synthetic particles that can deliver therapeutic drugs to a required area in the body. Now researchers say they have developed a new class of nanocarriers, prompting optimism in the long fight against aggressive cases of glioblastoma multiforme.
Researchers say that persistent and high inflammation in the brain affects connections relating to important symptoms that are currently difficult to treat, triggering up to a third of all cases of depression. And they believe their discovery can point to other therapeutic remedies for depression
Studying the bone microenvironment may offer new insights into better drugs for fighting prostate cancer metastasis.
A group of RNA experts say they've developed a potential upgrade for the wildly popular CRISPR/Cas9 gene editing tech that has been picked up in labs around the world.
Despite repeated assurances from rival camps that toxic loads of amyloid beta and tau are likely causes of Alzheimer's disease, no one is quite sure what is going on and clinical failures are routine. But investigators at UC San Diego School of Medicine say they have been garnering some preclinical clues that would suggest there could be a new pathway to follow in the clinic.
Actually eradicating the virus that causes AIDS has been thwarted by the virus' ability to hide out in dormant cells. Now researchers say that a generic alcoholism drug called disulfiram has demonstrated the ability to wake up the virus and flush it out for destruction.
Researchers at Baylor College of Medicine have published animal research that provides some proof that an experimental drug could one day provide a new therapeutic to effectively fight fat by pushing "bad" white fat to become "good" brown fat.
A team led by Janet Rubin at the University of North Carolina School of Medicine recently found a novel method to push stem cells into forming bone.
One of Takeda's experimental cancer therapies has been tested in a small group of advanced lymphoma patients, offering a snapshot of "modest" efficacy that could be amplified in earlier stage patients and in combination with other drugs.
Cambridge, MA-based Warp Drive Bio is launching a new cancer drug platform which the biotech claims will open up new, previously undruggable targets to developers.
After sequencing the DNA of patients suffering from severe diarrhea and their healthy relatives, researchers at Michigan State say they have identified a new microbiome strategy for aiding patients by better balancing levels of healthy and sickening gut bacteria.
Working with the knowledge that the CD44v6 protein acts as a co-receptor for receptor tyrosine kinases like MET and VEGFR-2 that drive pancreatic cancer, a group of German investigators say they've successfully tested a new peptide approach in mice that throws up a hurdle that can blunt and perhaps even stop the development of the disease.
Researchers at Case Western Reserve University School of Medicine have drawn an interesting link between the movement of protein in hair bundles and the signs of the repair and renewal mechanism. These findings hold promise in furthering our knowledge of the molecular changes in hearing loss, which could lead to new therapies in the clinic.
Researchers have combined the use of a nonfluorescent bacterial phytochrome with photoacoustic tomography imaging in cancerous tissue, resulting in high spatial resolution, increased penetration depth, and crucially, enhanced detection sensitivity with significantly reduced background signals.
Researchers at the Mayo Clinic say that inhibiting certain enzyme pathways in cells cut down on inflammation and reduced frailty, a pathway that could play a significant role in antiaging therapies.